18 ALLY Robotic Cataract Laser Systems ® (“ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ALLY installed base grew 77% and total laser installed base grew 20% over 3Q 202 4 ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc . (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the... Read More

ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc . (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The... Read More

ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O’Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory... Read More

18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology... Read More

ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units (“RSUs”). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs... Read More

ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted 10 newly-hired non-executive employees an aggregate of 3,090 restricted stock units (“RSUs”). The RSUs were granted as of June 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs... Read More

14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR”... Read More

Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon’s cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency of cataract surgery GENEVA and ORLANDO, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical... Read More

ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company’s common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering... Read More

31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company’s total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full... Read More

ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR’s management will host a conference call and... Read More

ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of February 3, 2025, as inducements material to each employee entering... Read More

ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,650 shares of the Company’s common stock. The options were granted as of January 2, 2025, as inducements material to each employee entering... Read More

ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted four newly-hired non-executive employees stock options to purchase an aggregate of 2,475 shares of the Company’s common stock. The options were granted as of December 8, 2024, as inducements material to each employee entering... Read More

ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will... Read More

24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO,... Read More

ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 650 shares of the Company’s common stock. The options were granted as of November 1, 2024, as inducements material to each employee entering... Read More

ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am... Read More

ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that more than one million procedures have been performed using its technology. “We are proud to celebrate this significant milestone with our surgeon partners. Our mission is to bring... Read More

ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of October 1, 2024, as inducements material to each employee entering... Read More

ORLANDO, Fla. / Sep 04, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,425 shares of the Company’s common stock. The options were granted as of September 3, 2024, as inducements material to each employee entering... Read More

ORLANDO, Fla. / Sep 04, 2024 / Business Wire / LENSAR ® , Inc . (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference On-demand presentation available Monday, September 9, 2024 at 7:00 a.m.... Read More

17 New ALLY ® Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval granted for commercial distribution of ALLY; First EU and Southeast Asia systems shipped Continued robust worldwide procedure growth; 2Q 2024 procedure volumes increased 19% over 2Q 2023 Installed system base grew 16% over 2Q... Read More

First EU ALLY Commercial Installation Planned for August 2024 ORLANDO, Fla. / Aug 07, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the ALLY Adaptive Cataract Treatment System (“ALLY” or “ALLY System”) has received certification under the European Union’s (“EU”)... Read More

ORLANDO, Fla. / Aug 01, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,925 shares of the Company’s common stock. The options were granted as of August 1, 2024, as inducements material to each employee entering... Read More

ORLANDO, Fla. / Aug 01, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the Company’s second quarter 2024 financial results will be released before market open on Thursday, August 8, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on... Read More

ORLANDO, Fla. / Jul 02, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,200 shares of the Company’s common stock. The options were granted as of July 2, 2024, as inducements material to each employee entering into... Read More

ORLANDO, Fla. / Jun 03, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,150 shares of the Company’s common stock. The options were granted as of June 3, 2024, as inducements material to each employee entering into... Read More

ORLANDO, Fla. / May 23, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 1:40 p.m. CT in... Read More

Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems ORLANDO, Fla. / May 09, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results... Read More

ORLANDO, Fla. / May 02, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET... Read More

ORLANDO, Fla. / May 01, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of May 1, 2024, as inducements material to each employee entering into... Read More

ORLANDO, Fla. / Apr 01, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock. The options were granted as of April 1, 2024, as inducements material to each employee entering... Read More

44 ALLY ® Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30, increasing the ALLY installed base to 54 and a backlog of 9 additional systems as of December 31, 2023 Total revenue increased 18% in the fourth quarter and 19% over full year 2022 ORLANDO, Fla. / Mar 04, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology... Read More

ORLANDO, Fla. / Mar 01, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company’s common stock. The options were granted as of March 1, 2024, as inducements material to each employee entering... Read More

ORLANDO, Fla. / Feb 26, 2024 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024. LENSAR’s management will host a conference call and webcast... Read More

Increased ALLY ® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of September 30, 2023 Total revenue increased 26% and U.S. procedure volume increased 16% over the third quarter 2022 ORLANDO, Fla. / Nov 09, 2023 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced... Read More

ORLANDO, Fla. / Nov 02, 2023 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023. LENSAR’s management will host a conference call and webcast at 8:30... Read More

Increased ALLY ® Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6 additional systems for installation as of June 30, 2023 U.S. procedure volumes increased 13% over second quarter 2022; 1H 2023 procedure volumes increased 15% year-over-year at sites that have upgraded from LENSAR Laser System (LLS) or added an ALLY $25.5 million cash available to support ongoing ALLY commercial launch... Read More

Private equity-owned ophthalmology group, EyeSouth Partners, adopts ALLY for each operating room within its Gainesville, Georgia and Boynton Beach, Florida Ambulatory Surgery Centers (ASCs) Private equity-owned ophthalmology groups account for 14% of the U.S. based ASCs performing cataract surgery 1 ALLY’s robust features and significantly improved surgical efficiencies gain support among private equity groups and physicians... Read More

Increased ALLY ® Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of May 12, 2023 U.S. procedure volumes increased 13% over first quarter 2022; Procedure volumes increased >20% year-over-year at sites that have upgraded from LENSAR Laser System (LLS) to ALLY Significantly strengthened balance sheet through $20 million private placement ORLANDO, Fla. / May 15, 2023 /... Read More

ORLANDO, Fla. / May 10, 2023 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2023 financial results will be released before market open on Monday, May 15, 2023. LENSAR’s management will host a conference call and webcast at... Read More

ORLANDO, Fla. / Mar 16, 2023 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives. “The reception to our next generation ALLY System... Read More

ORLANDO, Fla. / Mar 09, 2023 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023. LENSAR’s management will host a conference call... Read More

ORLANDO, Fla. / Feb 14, 2023 / Business Wire / LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 and its cash balance as of December 31, 2022, and provided an update on the launch of... Read More